<DOC>
	<DOCNO>NCT00644059</DOCNO>
	<brief_summary>This study evaluate efficacy , safety immunogenicity one two 0.25 mL 0.5 mL intramuscular injection adjuvanted influenza vaccine compare non-influenza non-adjuvanted influenza control vaccines subject 6 &lt; 72 month age .</brief_summary>
	<brief_title>Study Evaluate Efficacy , Safety Immunogenicity Influenza Vaccine Healthy Subjects ( Aged 6 &lt; 72 Months ) Versus Control Vaccines</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Children whose parents/legal guardian give write informed consent prior study entry : ) age 6 &lt; 72 month ( Part I II study ; influenza season 2007/2008 2008/2009 ) b ) age 6 &lt; 36 month ( Part III study ; influenza season 2009/2010 ) In good health determine : ) medical history , b ) physical examination , c ) clinical judgment investigator Exclusion criterion : Administration license vaccine ( include H1N1sw vaccine ) within 14 day ( inactivated vaccine ) 28 day ( live vaccine ) prior enrollment study . Routine vaccine , accord local recommendation , vaccine foresee protocol could give active trial phase ( i.e. , 21 day last vaccination ) conclude . Receipt another investigational vaccine investigational agent within 30 day prior enrollment study completion safety followup period another study , whichever longer , participation another clinical trial present study . Experience severe acute infectious disease month prior study start experience mild acute infection disease week prior study start ( untreated common cold acceptable ) . The severity infectious disease occur base investigator 's judgment . Any severe acute respiratory disease infection require systemic antibiotic antiviral therapy ongoing resolve within 2 day prior study start . Experience axillary temperature equal great 37.8°C ( rectal temperature equal great 38.3°C ) within 2 day enrollment . Any serious disease opinion investigator include , example : ) cancer , b ) autoimmune disease ( include rheumatoid arthritis immunosuppressive therapy ) , c ) insulin dependent diabetes mellitus , ) chronic pulmonary disease , asthma inhalative therapy acceptable , e ) acute progressive hepatic disease , f ) acute progressive renal disease . Known suspected impairment/alteration immune function , example , result : ) receipt immunosuppressive therapy ( corticosteroid except topical inhaled steroid cancer chemotherapy ) , b ) receipt immunostimulants , c ) receipt parenteral immunoglobulin preparation , blood product , and/or plasma derivative within past 90 day full length study , ) high risk develop immunocompromising disease ( suspect know HIV infection HIVrelated disease ) . Bleeding diathesis . History hypersensitivity component study medication chemically related substance . History anaphylaxis , serious vaccine reaction , allergy egg , egg product vaccine component . Laboratory confirm influenza disease . History neurological disorder seizure ( febrile seizure allow ) . Received influenza vaccine . Major surgery plan study period . Any condition , opinion investigator , might interfere evaluation study objective , e.g. , plan travel relocation residence would interfere completion study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>71 Months</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Influenza</keyword>
	<keyword>vaccine</keyword>
	<keyword>child</keyword>
</DOC>